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Epithelial ovarian cancer continues to be
the leading cause of death from gyneco-
logic cancers in the United States and
accounts for 14,400 deaths per year
(Ries et al., 2000). Ovarian cancer is
associated with a heavy burden of mor-
bidity and a high case-fatality rate
despite high cure rates for early stage
disease by surgical resection alone. This
apparent contradiction is explained by
the predominance of advanced stage
disease at presentation. Close to 70% of
women present with disease spread
beyond the pelvis, a group whose long-
term survival is only 29% (Piver et al.,
1993). While progress in defining optimal
adjuvant therapies for ovarian cancer
has resulted in a modest improvement in
disease-free and overall survival, an
exponential magnitude of difference
could be accomplished by downstaging
the disease at diagnosis through the
application of an effective screening tool.
To date, despite extensive evaluation,
the combination of physical examination,
imaging with transvaginal ultrasound,
and the serum marker CA-125 have not
resulted in acceptable sensitivity and
specificity levels, and the NIH
Consensus Statement published in 1994
(NIH, 1994) found no evidence to recom-
mend these screening modalities. A
recent article in Lancet by Petricoin et al.
describes what may be a major break-
through in this stalemate with the identifi-
cation of a proteomic pattern that dis-
criminated ovarian cancer from non-can-
cer with a positive predictive value of
94% (Petricoin et al., 2002).
An appreciation of the epidemiology
of epithelial ovarian cancer both sup-
ports the need to develop an effective
screening strategy and identifies sub-
sets of women who are likely to derive
the most benefit from this strategy. The
dominant risk factors, which include
advancing age, a family history of ovari-
an and/or breast cancer, and reproduc-
tive events that promote uninterrupted
ovulation, namely infertility and nullipari-
ty, are not easily amenable to modifica-
tion. The recent identification of the ovar-
ian cancer susceptibility genes, BRCA1,
BRCA2, and the HNPCC genes, has fur-
ther defined a group of women whose
lifetime risk for ovarian cancer may range
from 16% to 63% (Easton et al., 1995;
Streuwing et al., 1997). Several strate-
gies have attempted to improve positive
predictive values for ovarian cancer
screening. CA-125, the most extensively
studied biomarker in ovarian cancer, rep-
resents an antigenic determinant on 
a high molecular weight glycoprotein
which is expressed in structures derived
from coelomic epithelium. Elevated CA-
125 levels are found in approximately
85% of patients with epithelial ovarian
cancer, and this marker is routinely 
used to follow response to treatment.
However, expression of CA-125 is highly
correlated with tumor volume, and only
50% of patients with early stage disease
have elevated levels, thus limiting its use
as a screening tool (Jacobs and Bast,
1989). Skates et al. (1995) have pro-
posed the application of statistical mod-
eling to longitudinal serial CA-125
assays to create a predictive algorithm
that minimizes assay fluctuations and
relies on patterns over time rather than
isolated levels to improve predictive
probability. Others have suggested the
combination of panels of tumor-associat-
ed markers to improve efficacy. Some
candidate markers include ovarian 
carcinoma-associated antigen (OCA),
macrophage colony-stimulating factor
(MCS-F), a growth factor which stimu-
lates monocyte proliferation, lysophos-
phatidic acid (LPA), a bioactive phospho-
lipid with mitogenic and growth-factor-
like activity, CYFRA 21-1, a soluble
serum fragment of cytokeratin 19, and
tumor-associated trypsin inhibitor, a 6
kDa polypeptide, among others (Menon
and Jacobs, 2000; Ozols et al., 2000).
However, to date, no single marker or
combination of markers has emerged
with a clear advantage over CA-125
alone, and the search for the optimal
screening tool for ovarian cancer contin-
ues.
The approach taken by Petricoin et
al. (2002) represents a new direction in
this search, wherein a distinct pattern 
of proteins creates the discriminatory
power. Proteomics is a new and emerg-
ing technology that can identify 
low molecular weight molecules in a 
high-throughput, nonbiased discovery
approach using patient serum, plasma,
urine, or other secretions such as ascites
(Mills et al., 2001). Because of the vast
number of data points this technology
can generate, it is being linked to sophis-
ticated computer generated algorithms
to produce distinctive protein signatures
with high discriminatory potential.
The investigators used a dual-phase
approach. In the Pattern Discovery
phase, mass spectra generated by
SELDI-TOF from serum of affected and
high risk unaffected individuals were
compared. Using a combination of
genetic algorithms and cluster analysis,
a small set of key protein values
emerged that discriminated the cases
from the unaffected controls. In the
Pattern Matching phase, the optimum
pattern defined in Phase I was applied to
a new set of masked samples to assign
each sample to a predictive category. All
50 cancer samples were correctly cate-
gorized, including all 18 stage I cancers,
and 63 of 65 normal controls were cor-
rectly categorized, yielding a sensitivity
of 100% and a specificity of 95%.
Epidemiological and clinical features
of ovarian cancer, however, point out that
without additional refinements, the pro-
teomic results as reported will not be
useful for screening the general popula-
tion. Ovarian cancer is a relatively
uncommon disease. The screening pro-
gram must have a very high specificity,
greater than 99%, to achieve an accept-
able positive predictive value. A “positive”
screening test will trigger a diagnostic
procedure to determine if the woman has
ovarian cancer. An exploratory laparoto-
my remains the gold standard to diag-
nose ovarian cancer and is associated
with morbidity and, very rarely, mortality.
It has been generally accepted that a
screening test should result in no more
than 10 laparotomies to diagnose one
case of ovarian cancer. Since the preva-
lence of ovarian cancer is low (1 in
2500), a screening test which has a
specificity of only 95% (the proteomic
pattern) will result in far too many unnec-
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essary laparotomies to make it clinically
useful.The sensitivity of 100% in the pro-
teomic assay is encouraging, but
because of the low prevalence, a high
sensitivity does not significantly influ-
ence the false-positive laparotomy rate.
However, the false-positive rate can be
improved by either increasing the speci-
ficity of the test or by identifying a high-
risk population which will have a greater
prevalence of ovarian cancer. It remains
to be determined whether sequential
proteomic assays, or the use of this
assay in conjunction with other screen-
ing technologies, such as serum CA-125
levels or ultrasonography, will lead to
improvements in specificity that will
make the test clinically useful.
This approach does have several
potential advantages. It is minimally inva-
sive and uses small amounts of biospec-
imens in a fast and cost-effective man-
ner. The discriminatory power of the
applied statistical modeling will continue
to improve when the data set grows and
the specificity may become acceptable.
And apart from providing an effective
screening tool, evaluation of the protein
products that constitute the key cluster
has the potential to elucidate the under-
lying molecular processes of ovarian car-
cinogenesis. Clearly, several future
directions are indicated by this report.
First, validation of the findings in a large
prospective cohort with sufficient power
to assess the discriminatory power of the
analyses in subsets of women defined by
risk parameters, genetic status, stage,
and histopathologic type is needed.
Reproducibility among mass spec-
troscopy techniques and across instru-
mentation must precede widespread
application. Novel mathematical model-
ing approaches specifically tailored to
proteomic technology may further
advance the refinement of this approach.
And the application of this model to other
disease conditions could have unlimited
possibilities, both in the diagnostic and
treatment setting.
Recently, microarray technology has
also been used to identify novel potential
serum markers for early detection of
ovarian cancer. Mok et al. (2001) used
such a technique to identify overex-
pressed genes for secretory proteins as
potential serum biomarkers. RNA was
isolated from ovarian cancer cell lines
and from normal human ovarian surface
epithelial (HOSE) cells, and complemen-
tary DNA generated from these pools
was hybridized to a microarray slide to
identify genes overexpressed in cancer
cells. Prostasin, a serine protease nor-
mally secreted by the prostate gland,
was selected for further study. Prostasin
was then measured in the serum using
an enzyme-lined immunosorbent assay
in 64 patients with ovarian cancer and in
137 normal subjects.The resulting sensi-
tivity and specificity for prostasin in com-
bination with serum CA-125 resulted in
similar sensitivity (92%) and specificity
(94%) as reported with the proteomic
assay. At least 14 other candidate tumor
markers have been identified through
similar differential display technologies
of gene expression (Mills et al., 2001). It
is certainly possible that combinations of
microarray technology and proteomics
will lead to new algorithms for effective
screening for ovarian cancer.
Perhaps the most promising out-
come of the work reported by Petricoin et
al. (2002) is the interface between pro-
teomic technology and bioinformatics.
The rapid explosion in the amount of
data being generated by current genom-
ic and proteomic technologies already
exceeds the analytic capacity of the
human mind. The need for increasing
sophistication in data management and
statistical interpretation is underscored
by this paper, and attention to this aspect
of the research is critical to its successful
translation into clinical practice.
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